This is a routine insider onboarding filing with no trading or financial implications. Monitor future Form 4 filings from Tadvalkar for any insider transactions that may signal conviction or concern.
Price Chart
Executive Summary
Laura Tadvalkar filed a Form 3 initial statement of beneficial ownership with Hemab Therapeutics Holdings, Inc. (COAG), indicating she has become a reporting insider (officer, director, or >10% holder). The filing is administrative and includes a power of attorney authorizing others to file future SEC reports on her behalf. No financial data, share amounts, or transaction details are disclosed.
Key Facts
- Form 3 filed by Laura Tadvalkar as a new reporting insider of Hemab Therapeutics Holdings, Inc.
- Filing includes a power of attorney authorizing Mads Nikolaj Behrndt, Benny Sørensen, and Klaus Krainer Jønsson to file future SEC reports on her behalf.
- No beneficial ownership amounts or securities transactions are disclosed in the filing.
- The filing is dated April 30, 2026, with a period of report of April 30, 2026.
Financial Impact
No financial impact — the filing is a routine initial ownership disclosure with no monetary figures.
Risk Factors
- No material risks identified from this filing alone.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001193125-26-198198 |
| Document: 0001193125-26-198198-index-headers.html | 0001193125-26-198198 |
| Document: 0001193125-26-198198-index.html | 0001193125-26-198198 |
| Document: 0001193125-26-198198.txt | 0001193125-26-198198 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $49.87 $44.50 | ▼ −10.77% | ▼ −9.71% | $30.36 (−39.12%) |
Jun 17, 2026 15w ago | Insider Buy | $29.24 $44.53 | ▲ +52.29% | ▲ +51.76% | $30.36 (+3.83%) |
May 21, 2026 19w ago | Press Release | $26.30 $31.83 | ▲ +21.03% | ▲ +20.69% | $30.36 (+15.44%) |
May 4, 2026 21w ago | 8-K | $25.00 $27.47 | ▲ +9.88% | ▲ +4.93% | $30.36 (+21.44%) |
Apr 30, 2026 22w ago | Press Release | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access